Prudentia Sciences

Prudentia Sciences builds an AI-powered scientific intelligence platform for decision-making across the pharmaceutical, biotechnology, and investor communities engaged in life sciences dealmaking. The company is headquartered in Cambridge, Massachusetts, and was founded by a team with expertise spanning medicine, technology, and life sciences innovation.

The Prudentia Sciences Platform is an AI-native system that combines expert-developed frameworks, AI trained on drug development, and a unified evidence base. It produces science-grounded, decision-ready outputs for asset assessment, enabling faster evaluation and accelerated go/no-go decisions across time, cost, probability of success, and revenue dimensions. Its technical work spans artificial intelligence, machine learning, drug development AI, and life sciences data analytics, applied to processes that have traditionally been fragmented and labour-intensive.

The market it addresses is substantial: over $250 billion in annual life sciences business development, licensing, and M&A activity, with more than $1 trillion in capital awaiting investment opportunities. The company's stated mission is to accelerate investment in breakthrough therapies.